Literature DB >> 2535250

Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens.

S F Orencole1, C A Dinarello.   

Abstract

Most studies have shown that interleukin-1 (IL-1) acts as a helper or co-stimulator in T-lymphocyte activation and proliferation by mitogens or antigens. We describe here a stable subclone (D10S) of the murine D10.G4.1 helper T-cell which proliferates to subfemtomolar (attomolar) concentrations of IL-1 beta or alpha in the absence of mitogens. D10S cells have been maintained in culture for over two years without splenic cell feeder layers nor antigen stimulation. Detection of proliferation can be made by either uptake of tritiated thymidine at 72 h or in 48 h by a colorimetric assay which measures mitochondrial dehydrogenases; the latter assay is rapid and inexpensive. D10S cells are distinct from the parent clone D10.G4., which requires mitogens for IL-1 activity. IL-1-induced proliferation is independent of the elaboration of IL-2, IL-4, or IL-6, although these cells proliferate to these lymphokines at considerably higher concentrations when compared to IL-1. The D10S cells proliferate in direct correlation to the duration of IL-1 presence in the culture. We found no evidence that IL-1 induced more IL-1 in these cells. The subclone is highly specific for IL-1: proliferation was not observed to endotoxin, human or murine interferon-gamma (IFN gamma), tumor necrosis factor (TNF), lymphotoxin, or granulocyte-macrophage colony stimulating factor (GM-CSF). There was no suppressive effect of transforming growth factor (TGF beta). Only at high concentrations (100 ng/ml) did IL-6 induce proliferation. We conclude that this stable, feeder layer-free cell line is highly sensitive to IL-1 which acts as a direct stimulant for these cells; they are also useful for bioassays as well as the study of IL-1 receptors as described in the accompanying paper.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535250     DOI: 10.1016/1043-4666(89)91044-2

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  16 in total

1.  Glucocorticoid-induced keratinocyte-derived interleukin-1 receptor antagonist(s).

Authors:  S Stosić-Grujicić; M L Lukić
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

Review 2.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury.

Authors:  William B Gallentine; Shlomo Shinnar; Dale C Hesdorffer; Leon Epstein; Douglas R Nordli; Darrell V Lewis; L Matthew Frank; Syndi Seinfeld; Ruth C Shinnar; Karen Cornett; Binyi Liu; Solomon L Moshé; Shumei Sun
Journal:  Epilepsia       Date:  2017-04-27       Impact factor: 5.864

4.  Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS.

Authors:  H Loppnow; P Libby; M Freudenberg; J H Krauss; J Weckesser; H Mayer
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

Review 5.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

6.  Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

Authors:  Marianne Böni-Schnetzler; Jeffrey Thorne; Géraldine Parnaud; Lorella Marselli; Jan A Ehses; Julie Kerr-Conte; Francois Pattou; Philippe A Halban; Gordon C Weir; Marc Y Donath
Journal:  J Clin Endocrinol Metab       Date:  2008-07-29       Impact factor: 5.958

7.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model.

Authors:  J Dawson; C Rordorf-Adam; T Geiger; H Towbin; S Kunz; H Nguyen; O Zingel; D Chaplin; K Vosbeck
Journal:  Agents Actions       Date:  1993-03

9.  Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins.

Authors:  F Cominelli; C C Nast; R Llerena; C A Dinarello; R D Zipser
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

10.  Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression.

Authors:  K Ye; K C Koch; B D Clark; C A Dinarello
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.